141 related articles for article (PubMed ID: 26897866)
1. The role of biosimilar granulocyte colony stimulating factor (GCSF) Zarzio for progenitor cell mobilization and the treatment of therapy-induced neutropenia in adult hematopoietic stem cell transplantation.
Severson CC
Can Oncol Nurs J; 2015; 25(4):443-54. PubMed ID: 26897866
[TBL] [Abstract][Full Text] [Related]
2. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia.
Aapro M; Cornes P; Abraham I
J Oncol Pharm Pract; 2012 Jun; 18(2):171-9. PubMed ID: 21610020
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience.
Islami MM; Khan MA; Aseeri MA; Alshamrani MA; Alnatsheh A; Alamoudi S; Alzahrani AA
Ann Transplant; 2023 Mar; 28():e938585. PubMed ID: 36864713
[TBL] [Abstract][Full Text] [Related]
4. Mobilization of hematopoietic progenitor cells from allogeneic healthy donors using a new biosimilar G-CSF (Zarzio®).
Antelo ML; Zabalza A; Sánchez Antón MP; Zalba S; Aznar M; Mansilla C; Ramírez N; Olavarría E
J Clin Apher; 2016 Feb; 31(1):48-52. PubMed ID: 26011178
[TBL] [Abstract][Full Text] [Related]
5. Comparison of transplant outcomes and economic costs between biosimilar and originator filgrastim in allogeneic hematopoietic stem cell transplantation.
Harada K; Yamada Y; Konishi T; Nagata A; Takezaki T; Kaito S; Kurosawa S; Sakaguchi M; Yasuda S; Yoshioka K; Watakabe-Inamoto K; Igarashi A; Najima Y; Hagino T; Muto H; Kobayashi T; Doki N; Kakihana K; Sakamaki H; Ohashi K
Int J Hematol; 2016 Dec; 104(6):709-719. PubMed ID: 27565504
[TBL] [Abstract][Full Text] [Related]
6. [Biosimilar filgrastim: from development to record].
García Alfonso P
Farm Hosp; 2010 Mar; 34 Suppl 1():19-24. PubMed ID: 20920854
[TBL] [Abstract][Full Text] [Related]
7. Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment.
Publicover A; Richardson DS; Davies A; Hill KS; Hurlock C; Hutchins D; Jenner MW; Johnson PW; Lamb J; Launders H; McKeag N; Newman J; Orchard KH
Br J Haematol; 2013 Jul; 162(1):107-11. PubMed ID: 23614650
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).
Gascón P; Aapro M; Ludwig H; Bokemeyer C; Boccadoro M; Turner M; Denhaerynck K; MacDonald K; Abraham I
Support Care Cancer; 2016 Feb; 24(2):911-925. PubMed ID: 26306517
[TBL] [Abstract][Full Text] [Related]
9. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
Chen B; Nagai S; Armitage JO; Witherspoon B; Nabhan C; Godwin AC; Yang YT; Kommalapati A; Tella SH; DeAngelis C; Raisch DW; Sartor O; Hrushesky WJ; Ray PS; Yarnold PR; Love BL; Norris LB; Knopf K; Bobolts L; Riente J; Luminari S; Kane RC; Hoque S; Bennett CL
Oncologist; 2019 Apr; 24(4):537-548. PubMed ID: 30842244
[TBL] [Abstract][Full Text] [Related]
10. Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).
Roché H; Eymard JC; Radji A; Prevost A; Diab R; Lamuraglia M; Soumoudronga RF; Gasnereau I; Toledano A
BMC Cancer; 2018 Nov; 18(1):1127. PubMed ID: 30445935
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens.
Bassi S; Stroppa EM; Moroni CF; Arbasi MC; Trabacchi E; Di Franco A; Lazzaro A; Bernuzzi P; Moretto M; Arcari A; Bosi C; Riva A; Cavanna L; Vallisa D
Blood Transfus; 2015 Jul; 13(3):478-83. PubMed ID: 25761321
[TBL] [Abstract][Full Text] [Related]
12. Totality of the evidence at work: The first U.S. biosimilar.
Holzmann J; Balser S; Windisch J
Expert Opin Biol Ther; 2016; 16(2):137-42. PubMed ID: 26634611
[TBL] [Abstract][Full Text] [Related]
13. Filgrastim biosimilar (EP2006): A review of 15 years' post-approval evidence.
Gascón P; Harbeck N; Rapoport BL; Anderson R; Brueckmann I; Howe S; Aapro M
Crit Rev Oncol Hematol; 2024 Apr; 196():104306. PubMed ID: 38401695
[TBL] [Abstract][Full Text] [Related]
14. Biosimilar Filgrastim in Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization and Post-Transplant Hematologic Recovery.
Marchesi F; Mengarelli A
Curr Med Chem; 2016; 23(21):2217-29. PubMed ID: 27183986
[TBL] [Abstract][Full Text] [Related]
15. Clinical safety and efficacy of "filgrastim biosimilar 2" in Japanese patients in a post-marketing surveillance study.
Tamura K; Hashimoto K; Nishikawa K
J Infect Chemother; 2018 May; 24(5):363-369. PubMed ID: 29398477
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a conversion from filgrastim to filgrastim-sndz in stem cell transplant patients undergoing mobilization.
Curry LD; Anders B; Dressler EV; Kennedy L
J Oncol Pharm Pract; 2021 Jun; 27(4):871-876. PubMed ID: 32686616
[TBL] [Abstract][Full Text] [Related]
17. Biosimilars G-CSF versus originator G-CSF in post allotransplant recovery. A case-control study.
Targhetta C; Baronciani D; Capasso M; Depau C; Tandurella I; Giuseppina Corona M; Angelucci E
Am J Hematol; 2016 Feb; 91(2):E7-8. PubMed ID: 26596244
[No Abstract] [Full Text] [Related]
18. Tbo-Filgrastim: A Review in Neutropenic Conditions.
Blair HA; Scott LJ
BioDrugs; 2016 Apr; 30(2):153-60. PubMed ID: 27023705
[TBL] [Abstract][Full Text] [Related]
19. Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study.
Yousef CC; Khan MA; Almodaimegh H; Alshamrani M; Al-Foheidi M; AlAbdalkarim H; AlJedai A; Naeem A; Abraham I
J Med Econ; 2023; 26(1):394-402. PubMed ID: 36815700
[TBL] [Abstract][Full Text] [Related]
20. Comparison between biosimilar filgrastim vs other granulocyte-colony stimulating factor formulations (originator filgrastim, peg-filgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network.
Marchesi F; Cerchiara E; Dessanti ML; Gumenyuk S; Franceschini L; Palombi F; Pisani F; Romano A; Spadea A; Pupo L; Annibali O; La Malfa A; Arcese W; Mengarelli A
Br J Haematol; 2015 Apr; 169(2):293-6. PubMed ID: 25371286
[No Abstract] [Full Text] [Related]
[Next] [New Search]
